Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
Trevena, Inc. (TRVN)
Last trevena, inc. earnings: 3/12 07:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.trevena.com/investor-relations
Company Research
Source: GlobeNewswire
CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss oliceridine. At the meeting, the Advisory Committee voted 8 against, and 7 in favor of, the approval of oliceridine for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. “We continue to believe that the totality of evidence presented and discussed today supports the utility of oliceridine as a new analgesic option for the management of moderate to severe acute pain for patients in hospitals or other controlled clinical settings,” said Carrie L. Bourdow, President and Chief Executive Officer. “Trevena is committed to working closely with the FDA as they complete their review of the NDA for oliceridine.” The Advisory Committee reviewed data from oliceridine’s
Show less
Read more
Impact Snapshot
Event Time:
TRVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVN alerts
High impacting Trevena, Inc. news events
Weekly update
A roundup of the hottest topics
TRVN
News
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CustomerInsights.AI Announces Strategic Advisory Board Members for 2024 [Yahoo! Finance]Yahoo! Finance
TRVN
Earnings
- 8/14/23 - Miss
TRVN
Sec Filings
- 3/21/24 - Form DEFA14A
- 3/21/24 - Form 8-K
- 3/6/24 - Form 8-K
- TRVN's page on the SEC website